Stacy Griffin, MD
Allergy & Immunology · Little Rock, ARNPI 1407892805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 526 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,604, 2.3 times the $1,140 reported in 2019.
Across 526 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Sanofi$926
- Regeneron Healthcare Solutions, Inc.$846
- CSL Behring$829
- Genentech USA, Inc.$732
- plus $3K from 30 others
What the payments were for
- Consulting fees$240%
- Food & beverage$9,70899%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 129 | $1,661 |
| AstraZeneca | 59 | $1,558 |
| Sanofi | 37 | $926 |
| Regeneron Healthcare Solutions, Inc. | 36 | $846 |
| CSL Behring | 43 | $829 |
| Genentech USA, Inc. | 49 | $732 |
| Novartis | 29 | $583 |
| Grifols USA, LLC | 16 | $306 |
| LEO Pharma Inc. | 18 | $304 |
| Amgen | 12 | $286 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $209 |
| Kaleo, Inc. | 11 | $196 |
| Pfizer | 12 | $167 |
| Pharming Healthcare, Inc. | 7 | $165 |
| Optinose US, Inc. | 9 | $126 |
| Lilly USA, LLC | 5 | $98 |
| Shire North American Group Inc | 5 | $80 |
| Hikma Pharmaceuticals USA | 4 | $74 |
| Octapharma USA, Inc. | 1 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Biocryst US Sales Co., LLC | 2 | $62 |
| Blueprint Medicines Corporation | 2 | $59 |
| Verona Pharma, Inc. | 2 | $42 |
| GC Biopharma USA, Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $40 |
| Greer Laboratories, Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Boehringer Ingelheim | 3 | $37 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| USWM, LLC | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Merck | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,804 in reported general payments places this provider in the 80th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 25 | $74,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $38,566 |
| Arnuity ElliptaFluticasone Furoate | 53 | $15,733 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,287 |
| Epinephrine | 41 | $9,528 |
| Pulmicort FlexhalerBudesonide | 27 | $7,177 |
| Azelastine Hcl | 237 | $6,462 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $5,460 |
| DuleraMometasone/Formoterol | 11 | $3,959 |
| Fluticasone Propionate | 229 | $3,196 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,196 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $2,576 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $2,428 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,376 |
| Montelukast Sodium | 225 | $1,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $1,661 | $54,29996 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $1,558 | $18,46463 claims |
| Hikma Pharmaceuticals USAEpinephrine | $74 | $9,52841 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $36 | $5,46013 claims |
| MerckDulera | $16 | $3,95911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Karl SitzLittle Rock$19K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Adam PriceLittle Rock$4K
- Lori KagyLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.